Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
U-Neuron Biomedical's basic earnings per share (Basic EPS) for the
six
months ended in Jun. 2026 was NT$-0.72.
Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Jun. 2026 was NT$-1.55.
U-Neuron Biomedical's EPS without NRI for the
six
months ended in Jun. 2026 was NT$-0.72.
Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2026 was -1.55.
During the past 3 years, the average EPS without NRIGrowth Rate was 19.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
During the past 6 years, U-Neuron Biomedical's highest 3-Year average EPS without NRI Growth Rate was 19.30% per year. The lowest was -23.70% per year. And the median was -2.20% per year.
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
U-Neuron Biomedical EPS (Basic) Related Terms
U-Neuron Biomedical EPS (Basic) Historical Data
* Premium members only.
The historical data trend for U-Neuron Biomedical's EPS (Basic) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.
U-Neuron Biomedical's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as
EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-1.55
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
U-Neuron Biomedical (ROCO:6973) has a EPS (Basic) of NT$-1.55 as of Jun. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on U-Neuron Biomedical and its competitors.
Is U-Neuron Biomedical's EPS (Basic) too high?
U-Neuron Biomedical's current EPS (Basic) is NT$-1.55. Overall, U-Neuron Biomedical has a GF Score™ of 32/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does U-Neuron Biomedical's EPS (Basic) compare to VRTX and REGN?
U-Neuron Biomedical's EPS (Basic) of NT$-1.55 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on U-Neuron Biomedical and its competitors. U-Neuron Biomedical's current EPS (Basic) is NT$-1.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is U-Neuron Biomedical stock overvalued right now?
Based on GuruFocus' analysis, U-Neuron Biomedical (ROCO:6973) is currently considered Possible Value Trap. The stock's GF Value™ is NT$70.22, compared to a current price of NT$41.35 — trading 41.1% below its estimated fair value. The current EPS (Basic) is NT$-1.55. U-Neuron Biomedical's overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For U-Neuron Biomedical (ROCO:6973), the current EPS (Basic) is NT$-1.55 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is U-Neuron Biomedical (ROCO:6973) Overvalued in 2026?
Based on GuruFocus' analysis, U-Neuron Biomedical stock appears to be undervalued.
The current stock price of NT$41.35 is trading 41.1% below its estimated GF Value™ of NT$70.22.
GuruFocus considers U-Neuron Biomedical to be Possible Value Trap.
Key valuation signals for ROCO:6973:
EPS (Basic): NT$-1.55
GF Value™: NT$70.22 vs. price of NT$41.35 (41.1% below fair value)
No single metric tells the full story. See the ROCO:6973 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
U-Neuron Biomedical Inc is engaged in research and development of stem cell storage & separation technology, and treatment application technology. It has patent on the Technology of Culture and Isolation of Amniotic Fluid Stem Cell.
32GF Score
Get the complete analysis for ROCO:6973
EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6973 has been successfully added to your 
